Search research articles
Contact Us
Filters
Showing results (11-20 of 663) with videos related to
Page
of 67
Sort By:
World Journal of Gastroenterology
|
February 28, 2014
How to select the optimal treatment for first line metastatic colorectal cancer
Alexander Stein, Carsten Bokemeyer
Onkologie
|
October 8, 2010
[Clinical trials and personalized medicine in oncology?]
Dirk Arnold, Carsten Bokemeyer
Onkologie
|
October 6, 2005
[Passive immunotherapy with monoclonal antibodies]
Carsten Bokemeyer, Jens Panse
Current Opinion in Urology
|
June 30, 2018
Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer
Christoph Oing, Carsten Bokemeyer
Der Onkologe : Organ Der Deutschen Krebsgesellschaft E.V
|
January 11, 2021
[Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib]
Christoph Oing, Carsten Bokemeyer
Deutsche Medizinische Wochenschrift (1946)
|
June 24, 2017
[New Aspects in Treatment of Metastatic Prostate Cancer]
Gunhild von Amsberg, Carsten Bokemeyer
Pharmazie in Unserer Zeit
|
April 5, 2005
[The action and toxicity of taxanes]
Hans-Peter Lipp, Carsten Bokemeyer
Lung Cancer (Amsterdam, Netherlands)
|
July 22, 2010
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
Eckart Laack, Guido Sauter, Carsten Bokemeyer
British Journal of Haematology
|
March 16, 2004
Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy?
Carsten Bokemeyer, Tim Littlewood, Matti Aapro
Cancer
|
February 8, 2006
Recent advances in management of patients with platinum-refractory testicular germ cell tumors
Christian Kollmannsberger, Craig Nichols, Carsten Bokemeyer
Page
of 67
Search research articles
Search
Showing results (11-20 of 663) with videos related to
Sort By:
Page
of 67
World Journal of Gastroenterology
|
February 28, 2014
How to select the optimal treatment for first line metastatic colorectal cancer
Alexander Stein, Carsten Bokemeyer
Onkologie
|
October 8, 2010
[Clinical trials and personalized medicine in oncology?]
Dirk Arnold, Carsten Bokemeyer
Onkologie
|
October 6, 2005
[Passive immunotherapy with monoclonal antibodies]
Carsten Bokemeyer, Jens Panse
Current Opinion in Urology
|
June 30, 2018
Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer
Christoph Oing, Carsten Bokemeyer
Der Onkologe : Organ Der Deutschen Krebsgesellschaft E.V
|
January 11, 2021
[Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib]
Christoph Oing, Carsten Bokemeyer
Deutsche Medizinische Wochenschrift (1946)
|
June 24, 2017
[New Aspects in Treatment of Metastatic Prostate Cancer]
Gunhild von Amsberg, Carsten Bokemeyer
Pharmazie in Unserer Zeit
|
April 5, 2005
[The action and toxicity of taxanes]
Hans-Peter Lipp, Carsten Bokemeyer
Lung Cancer (Amsterdam, Netherlands)
|
July 22, 2010
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer
Eckart Laack, Guido Sauter, Carsten Bokemeyer
British Journal of Haematology
|
March 16, 2004
Is once-weekly epoetin beta 'highly effective' in treating anaemia in patients with lymphoproliferative malignancy?
Carsten Bokemeyer, Tim Littlewood, Matti Aapro
Cancer
|
February 8, 2006
Recent advances in management of patients with platinum-refractory testicular germ cell tumors
Christian Kollmannsberger, Craig Nichols, Carsten Bokemeyer
Page
of 67